Literature DB >> 36273365

A multicenter international prospective study of the validity and reliability of a COVID-19-specific health-related quality of life questionnaire.

Cecilie Delphin Amdal1,2, Ragnhild Sørum Falk3, Susanne Singer4, Madeline Pe5, Claire Piccinin5, Andrew Bottomley5, Lambert Tetteh Appiah6, Juan Ignacio Arraras7, Oliver Bayer4, Eirik Alnes Buanes8,9, Anne Sophie Darlington10, Gracia Dekanic Arbanas11, Kristin Hofsø12,13, Bernard Holzner14, Pernilla Sahlstrand-Johnson15, Dagmara Kuliś5, Ghansyam Parmar16, Niveen M E Abu Rmeileh17, Melanie Schranz4, Samantha Sodergren10, Kristin Bjordal3,18.   

Abstract

PURPOSE: To develop and validate a health-related quality of life (HRQoL) questionnaire for patients with current or previous coronavirus disease (COVID-19) in an international setting.
METHODS: This multicenter international methodology study followed standardized guidelines for a four-phase questionnaire development. Here, we report on the pretesting and validation of our international questionnaire. Adults with current or previous COVID-19, in institutions or at home were eligible. In the pretesting, 54 participants completed the questionnaire followed by interviews to identify administration problems and evaluate content validity. Thereafter, 371 participants completed the revised questionnaire and a debriefing form to allow preliminary psychometric analysis. Validity and reliability were assessed (correlation-based methods, Cronbach's α, and intra-class correlation coefficient).
RESULTS: Eleven countries within and outside Europe enrolled patients. From the pretesting, 71 of the 80 original items fulfilled the criteria for item-retention. Most participants (80%) completed the revised 71-item questionnaire within 15 min, on paper (n = 175) or digitally (n = 196). The final questionnaire included 61 items that fulfilled criteria for item retention or were important to subgroups. Item-scale correlations were > 0.7 for all but nine items. Internal consistency (range 0.68-0.92) and test-retest results (all but one scale > 0.7) were acceptable. The instrument consists of 15 multi-item scales and six single items.
CONCLUSION: The Oslo COVID-19 QLQ-W61© is an international, stand-alone, multidimensional HRQoL questionnaire that can assess the symptoms, functioning, and overall quality of life in COVID-19 patients. It is available for use in research and clinical practice. Further psychometric validation in larger patient samples will be performed.
© 2022. The Author(s).

Entities:  

Keywords:  COVID-19; HRQoL; PROM; Patient-reported outcome measure; Quality of life; Questionnaire

Year:  2022        PMID: 36273365     DOI: 10.1007/s11136-022-03272-2

Source DB:  PubMed          Journal:  Qual Life Res        ISSN: 0962-9343            Impact factor:   3.440


  5 in total

1.  COVID-19-related Conjunctivitis Review: Clinical Features and Management.

Authors:  William Binotti; Pedram Hamrah
Journal:  Ocul Immunol Inflamm       Date:  2022-04-08       Impact factor: 3.070

2.  Agreement between patient-reported symptoms and their documentation in the medical record.

Authors:  Serguei V Pakhomov; Steven J Jacobsen; Christopher G Chute; Veronique L Roger
Journal:  Am J Manag Care       Date:  2008-08       Impact factor: 2.229

3.  The Greek Collaborative Long COVID Study: Non-Hospitalized and Hospitalized Patients Share Similar Symptom Patterns.

Authors:  Martha-Spyridoula Katsarou; Eleni Iasonidou; Alexander Osarogue; Efthymios Kalafatis; Maria Stefanatou; Sofia Pappa; Stylianos Gatzonis; Anastasia Verentzioti; Pantelis Gounopoulos; Christos Demponeras; Eleni Konstantinidou; Nikolaos Drakoulis; Andreas Asimakos; Archontoula Antonoglou; Aspasia Mavronasou; Stavroula Spetsioti; Anastasia Kotanidou; Paraskevi Katsaounou
Journal:  J Pers Med       Date:  2022-06-17

4.  Long COVID and chronic COVID syndromes.

Authors:  Stephen Halpin; Rory O'Connor; Manoj Sivan
Journal:  J Med Virol       Date:  2020-10-30       Impact factor: 20.693

5.  Patient-reported outcome measures after COVID-19: a prospective cohort study.

Authors:  Alyson W Wong; Aditi S Shah; James C Johnston; Christopher Carlsten; Christopher J Ryerson
Journal:  Eur Respir J       Date:  2020-11-26       Impact factor: 16.671

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.